Document is current
Any future updates will be listed below
-
Authors
Heming, Michael https://orcid.org/0000-0002-9568-2790
Börsch, Anna-Lena
Wiendl, Heinz
Meyer zu Hörste, Gerd https://orcid.org/0000-0002-4341-4719
-
Funding
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (ME4050/13-1, ME4050/13-1)
Interdisciplinary Center for Clinical Research Münster (MzH3/020/20, SEED/016/21)
Deutsche Forschungsgemeinschaft (ME4050/8-1)
- License Information
-
More Information
Article History
Received: 31 January 2022
Accepted: 28 July 2022
First Online: 17 August 2022
Change Date: 15 January 2023
Change Type: Update
Change Details: Missing Open Access funding information has been added in the Funding Note.
Declarations
:
: Not applicable.
: Not applicable.
: G.M.z.H. received compensation for serving on scientific advisory boards (Alexion) and speaker honoraria (Alexion). H.W. is acting as a paid consultant for AbbVie, Actelion, Biogen, IGES, Johnson & Johnson, Novartis, Roche, Sanofi-Aventis, and the Swiss Multiple Sclerosis Society. The remaining authors declare that they have no competing interests.
